Dynavax (NASDAQ: DVAX) reported Q2 EPS of $0.03, $0.12 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $56 million versus the consensus estimate of $48.39 million.

GUIDANCE:

Dynavax sees Q3 2023 revenue of $200-215 million, versus the consensus of $193.2 million.

For earnings history and earnings-related data on Dynavax (DVAX) click here.